Next Century Growth Investors LLC reduced its position in shares of Cryoport, Inc. (NASDAQ:CYRX) by 42.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,310 shares of the consumer goods maker’s stock after selling 38,292 shares during the period. Next Century Growth Investors LLC owned about 0.11% of Cryoport worth $3,300,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WCM Investment Management LLC boosted its position in shares of Cryoport by 5.5% during the second quarter. WCM Investment Management LLC now owns 141,816 shares of the consumer goods maker’s stock worth $8,949,000 after buying an additional 7,420 shares during the period. Geode Capital Management LLC boosted its position in shares of Cryoport by 22.8% during the first quarter. Geode Capital Management LLC now owns 713,954 shares of the consumer goods maker’s stock worth $37,132,000 after buying an additional 132,756 shares during the period. Redwood Investments LLC boosted its holdings in Cryoport by 14.9% in the second quarter. Redwood Investments LLC now owns 301,088 shares of the consumer goods maker’s stock valued at $18,999,000 after purchasing an additional 38,997 shares during the period. Waddell & Reed Financial Inc. purchased a new position in Cryoport in the first quarter valued at $3,863,000. Finally, Morgan Stanley boosted its holdings in Cryoport by 24.0% in the first quarter. Morgan Stanley now owns 267,528 shares of the consumer goods maker’s stock valued at $13,915,000 after purchasing an additional 51,770 shares during the period. Institutional investors and hedge funds own 87.29% of the company’s stock.
In other news, Director Daniel M. Hancock sold 574 shares of the firm’s stock in a transaction on Thursday, September 2nd. The stock was sold at an average price of $67.18, for a total value of $38,561.32. Following the completion of the transaction, the director now owns 5,201 shares in the company, valued at $349,403.18. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Daniel M. Hancock sold 10,000 shares of the firm’s stock in a transaction on Monday, September 27th. The shares were sold at an average price of $70.17, for a total value of $701,700.00. The disclosure for this sale can be found here. In the last three months, insiders sold 370,574 shares of company stock valued at $22,440,261. 10.90% of the stock is owned by corporate insiders.
Shares of NASDAQ CYRX traded up $0.23 during mid-day trading on Thursday, hitting $68.08. 280 shares of the company were exchanged, compared to its average volume of 414,412. Cryoport, Inc. has a 1-year low of $39.10 and a 1-year high of $84.97. The company has a quick ratio of 10.49, a current ratio of 10.79 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $63.58 and a 200-day simple moving average of $59.25. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of -35.71 and a beta of 0.89.
Cryoport (NASDAQ:CYRX) last released its earnings results on Thursday, August 5th. The consumer goods maker reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Cryoport had a negative net margin of 18.85% and a positive return on equity of 2.35%. The business had revenue of $56.19 million during the quarter, compared to analyst estimates of $51.23 million. Analysts anticipate that Cryoport, Inc. will post -0.57 earnings per share for the current fiscal year.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Featured Story: Strangles
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.